Lung Cancer, Metastatic Cancer
Conditions
Keywords
stage IV non-small cell lung cancer, recurrent non-small cell lung cancer, tumors metastatic to brain
Brief summary
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Gefitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving radiation therapy together with either gefitinib or temozolomide may kill more tumor cells. PURPOSE: This randomized phase II trial is studying how well giving radiation therapy together with either gefitinib or temozolomide works in treating patients with non-small cell lung cancer and brain metastases.
Detailed description
OBJECTIVES: Primary * Compare the efficacy of whole-brain radiotherapy combined with either gefitinib or temozolomide, in terms of overall survival, in patients with non-small cell lung cancer and brain metastases. Secondary * Compare the tolerability and toxicity of these regimens in these patients. * Compare the time to neurological disease progression, time to extracranial disease progression, and time to overall disease progression, in patients treated with these regimens. * Compare adverse events in patients treated with these regimens. * Compare cognitive function and quality of life of patients treated with these regimens. OUTLINE: This is a randomized, open-label, parallel-group, multicenter study. Patients are stratified according to extracranial disease (yes vs no), number of brain metastases (1-3 vs ≥ 4), prior chemotherapy (yes vs no), WHO performance status (0-1 vs 2), and participating center. Patients are randomized to 1 of 2 treatment arms. * Arm I: Patients undergo whole-brain radiotherapy (WBRT) once daily on days 1-5 and 8-12 and receive oral gefitinib once daily on days 1-28. Gefitinib treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity. * Arm II: Patients undergo WBRT as in arm I and receive oral temozolomide once daily on days 1-21. Temozolomide treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity. Quality of life is assessed at baseline and on day 1 of courses 2, 3, and 5. After completion of study therapy, patients are followed every 3 months. PROJECTED ACCRUAL: A total of 30-86 patients (15-43 per treatment arm) will be accrued for this study within 3 years.
Interventions
DRUGgefitinib
Once daily during days 1-28
DRUGtemozolomide
Once daily on days 1-21
RADIATIONradiation therapy
Whole brain radiotherapy
Sponsors
Swiss Cancer Institute
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
DISEASE CHARACTERISTICS: * Histologically or cytologically confirmed non-small cell lung cancer AND newly diagnosed brain metastases meeting 1 of the following criteria: * Multiple brain metastases * Single brain metastasis not amenable to potentially curative treatment * No advanced extracranial disease severely compromising vital functions and performance PATIENT CHARACTERISTICS: Age * 18 and over Performance status * WHO 0-2 Life expectancy * Not specified Hematopoietic * Hemoglobin \> 10 g/dL * Absolute neutrophil count \> 1,500/mm\^3 * Platelet count \> 100,000/mm\^3 Hepatic * Bilirubin ≤ 1.5 times upper limit of normal (ULN) * AST and ALT ≤ 2.5 times ULN * Alkaline phosphatase ≤ 2.5 times ULN (5 times ULN in the presence of documented bone metastases) * No unstable or uncompensated hepatic disease that would preclude study participation Renal * Creatinine clearance ≥ 40 mL/min * No unstable or uncompensated renal disease that would preclude study participation Cardiovascular * No myocardial infarction within the past 3 months * No unstable or uncompensated cardiac disease that would preclude study participation Pulmonary * No clinically active interstitial lung disease * Patients with chronic stable radiographic changes who are asymptomatic eligible * No other unstable or uncompensated respiratory disease that would preclude study participation Other * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception during and for 12 months after completion of study treatment * No nausea, vomiting, inability to swallow whole tablets/capsules, or malabsorption syndrome that would preclude oral medication ingestion or absorption * No psychiatric disorder that would preclude giving informed consent or study compliance * No active infection * No uncontrolled diabetes mellitus * No other medical condition that would preclude study participation PRIOR CONCURRENT THERAPY: Biologic therapy * Not specified Chemotherapy * No prior temozolomide Endocrine therapy * Concurrent corticosteroids allowed provided dose has been stable or decreasing for ≥ 4 days before study entry Radiotherapy * No prior brain irradiation Surgery * Not specified Other * No prior gefitinib or erlotinib * More than 30 days since prior investigational clinical trial participation * No other concurrent experimental drugs * No other concurrent anticancer therapy * No concurrent treatment with any of the following: * Phenytoin * Carbamazepine * Rifampin * Barbiturates * Hypericum perforatum (St. John's wort) * Other enzyme-inducing anti-epileptic drugs or tuberculostatic treatments * Any drug that contraindicates administration with study drugs
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall survival | life-long |
Secondary
| Measure | Time frame |
|---|---|
| Time to progression | 28 days |
| Time to neurological progression | 28 days |
| Time to extracranial disease progression | 28 days |
| Adverse events as measured at completion of study treatment | 28 days |
Countries
Switzerland
Outcome results
None listed